Emedastine transdermal - Hisamitsu Pharmaceutical

Drug Profile

Emedastine transdermal - Hisamitsu Pharmaceutical

Alternative Names: Emedastine fumarate; HP-3060

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Antiallergics; Antihistamines; Benzimidazoles; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinitis

Most Recent Events

  • 10 May 2017 Hisamitsu Pharmaceutical completes a phase III trial in Allergic rhinitis in Japan (Transdermal) (JapicCTI153092)
  • 10 May 2017 Hisamitsu Pharmaceutical completes a phase III trial in perennial Allergic rhinitis (In adolescents, In adults) in Japan (Transdermal) (JapicCTI152976)
  • 30 May 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top